



06.30.2012

INTERIM REPORT

PROFILE

STRATEC DEVELOPS AND MANUFACTURES FULLY AUTOMATED ANALYZER SYSTEMS BASED ON ITS OWN PATENTED TECHNOLOGIES FOR ITS PARTNERS IN THE FIELDS OF CLINICAL DIAGNOSTICS AND BIOTECHNOLOGY. STRATEC'S PARTNERS ARE MOSTLY GLOBAL PLAYERS OPERATING IN THE IN-VITRO DIAGNOSTICS INDUSTRY. THESE COMPANIES MARKET STRATEC'S SYSTEMS UNDER THEIR OWN NAMES, IN GENERAL TOGETHER WITH THEIR OWN REAGENTS, AS SYSTEM SOLUTIONS TO LABORATORIES, BLOOD BANKS, AND RESEARCH INSTITUTES AROUND THE WORLD.

CONTENTS

- 03 HIGHLIGHTS / KEY GROUP FIGURES AT A GLANCE
- 04 FOREWORD BY THE BOARD OF MANAGEMENT
- 05 INTERIM GROUP MANAGEMENT REPORT
- 09 CONSOLIDATED BALANCE SHEET
AS OF JUNE 30, 2012
- 11 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(total cost method) for the Period from April 1 to June 30, 2012
- 12 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(total cost method) for the Period from January 1 to June 30, 2012
- 13 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(cost of sales method) for the Period from January 1 to June 30, 2012
- 14 CONSOLIDATED CASH FLOW STATEMENT
for the Period from January 1 to June 30, 2012
- 15 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
for the Period from January 1 to June 30, 2012
- 17 NOTES TO THE GROUP INTERIM REPORT
for the Period from January 1 to June 30, 2012
- 20 ADDITIONAL INFORMATION

HIGHLIGHTS

Sales of € 55.0 million* in Q1-Q2/2012
(+13.3%; Q1-Q2/2011: € 48.5 million)

EBIT margin of 17.1%* in Q1-Q2/2012
(Q1-Q2/2011: 18.7%)

Consolidated net income of € 7.4 million in Q1-Q2/2012
(+5.6%; Q1-Q2/2011: € 7.0 million)

Earnings per share of € 0.63 in Q1-Q2/2012
(+5.0%; Q1-Q2/2011: € 0.60)

Company forecast confirmed

KEY GROUP FIGURES AT A GLANCE

in € thousands	01.01.-06.30.2012	01.01.-06.30.2011	Change
Sales	58,242	48,515	+20.0%
Adjusted sales*	54,974	48,515	+13.3%
Overall performance	60,870	54,800	+11.1%
EBITDA	11,443	10,750	+6.5%
EBIT	9,423	9,078	+3.8%
EBIT margin (%)*	17.1	18.7	-
Consolidated net income	7,352	6,964	+5.6%
Earnings per share (€)	0.63	0.60	+5.0%
No. of employees (absolute)	524	466	+12.5%

in € thousands	06.30.2012	12.31.2011	Change
Shareholders' equity	84,622	83,231	+1.7%
Total assets	115,942	110,997	+4.5%
Equity ratio (%)	73.0	75.0	-

* adjusted for a one-off item in the first quarter of 2012 due to an earnings-neutral transfer of unfinished services and prepayments received of € 3.3 million due to the impairment of a development project. Unadjusted sales amounted to € 58.2 million and the resultant EBIT margin amounted to 16.2%.

FOREWORD BY THE BOARD OF MANAGEMENT

Dear Shareholders,

In the past, various experts reported that our industry was undergoing a period in which the world's leading diagnostics companies had begun to outsource the development and production of their most important automation solutions to external partners. We can confirm this – it more or less represents a paradigm shift in the industry. Not least to account for this, STRATEC has laid foundations to benefit disproportionately from this trend and has accordingly stepped up its development work on new projects and feasibility studies. It goes without saying that these measures are not without implications for the development in our margin. With the course we have taken, we believe that we have found a balance that does justice both to our shareholders' interests and to those of our customers, and which will in particular promote the company's sustainably positive performance in the long term.

Our performance in the first half of 2012 was on target and was chiefly affected by the aforementioned expansion in our development activities. Serial production for the systems most recently launched onto the market by our customers was further ramped up and is set to be further optimized in the coming months. The market launches of two additional systems are scheduled to take place in the near future. Here too, we are currently in the ramp-up stage, during which we prepare the systems for serial production. Adjusted for a one-off item resulting from the reclassification of prepayments received and work in progress in connection with the impairment of a development project in the first quarter, our sales for the first six months of 2012 grew year-on-year by 13.3 % to € 55.0 million. Thereby we generated an EBIT margin of 17.1 % and consolidated net income of € 7.4 million, corresponding to earnings per share of € 0.63 for the first half of 2012.

We expect to see further positive momentum in the coming quarters both in terms of new market launches by our customers, and of our ability to publish new development cooperations.

Birkenfeld, July 2012

The Board of Management of
STRATEC Biomedical AG



Marcus Wolfinger



Dr. Robert Siegle



Bernd M. Steidle

INTERIM GROUP MANAGEMENT REPORT

REPORT ON THE EARNINGS, FINANCIAL AND NET ASSET POSITION

Sales for the first six months of the 2012 financial year grew by 20.0% to € 58.2 million (previous year: € 48.5 million). Despite the reclassification within equity of a milestone payment, the overall performance rose by 11.8% to € 60.9 million (previous year: € 54.8 million). The cost of materials also increased over the same period by 11.8% from € 25.7 million to € 28.8 million.

The stepping up in development activities, accompanied by a further expansion in production capacities, led personnel expenses to rise from € 14.1 million to € 16.6 million.

At € 4.7 million, other operating expenses remained unchanged on the previous year. Depreciation and amortization increased to € 2.0 million, while net financial expenses deteriorated to € -0.1 million. STRATEC thus generated consolidated net income of € 7.4 million in the period under report (previous year: € 7.0 million), corresponding to earnings per share of € 0.63 (previous year: € 0.60).

Due to the forthcoming market launches of two systems and the increase in development services, inventories rose by € 4.0 million. Total receivables and other assets increased from € 23.1 million to € 25.3 million. As a result of the dividend payment, cash and cash equivalents fell from € 19.5 million to € 17.7 million despite the positive cash flow of € 5.6 million from operating activities.

The equity ratio amounts to 73.0%. Non-current financial liabilities could be reduced to € 8.7 million. The increase in trade payables was driven by higher procurement volumes for raw materials and supplies. Within other current liabilities, an amount of around € 8.2 million has been reported for prepayments received for development services.

The inflow of funds from operating activities amounted to € 5.6 million, thus more than doubling compared with the previous year. The STRATEC Group invested € 1.1 million in the first six months of the 2012 financial year (previous year: € 1.5 million; previous year's figure includes construction activities of € 0.5 million).

CHANGES IN THE BUSINESS ENVIRONMENT AND IMPLICATIONS FOR STRATEC

In its latest forecast, the International Monetary Fund (IMF) has reduced its growth forecast for the global economy for the current year and for next year. The global economy risks losing further momentum given new tensions on the financial markets and the sovereign debt crisis in the euro area. A slowing in global growth trends had already been observed in the previous three months.

For the global economy, the IMF has now forecast growth of 3.5% in the current year, and 3.9% next year. Compared with the April forecast, these figures represent reductions of around 0.1% for 2012 and around 0.2% for 2013. The IMF has left its economic growth forecast for the euro area for the current year unchanged at minus 0.3%, but reduced its forecast for next year by 0.2 percentage points to growth of 0.7%. The IMF is also concerned about the USA, where the latest data indicate a slowdown in the factors driving growth. Similar concerns apply to countries such as Brazil, China, and India. Overall, however, emerging economies had so far weathered the crisis in impressive shape.

Global demographic developments represent one of the most serious challenges facing the world. The dynamic growth in the world's population, together with an unprecedented increase in the elderly share of the population and the sharp rise in the number of people with access to medical care, represent key factors which will shape the 21st century. This situation is accompanied by scientific and technological progress, which is opening up ever new possibilities in the fields of medicine, research, diagnostics and life science.

These developments will lead not only to an increase in the numbers of clinical diagnostics tests to be performed, but will also result in new, unique business opportunities for which STRATEC is optimally positioned with its automation solutions and on which it will continue to focus its strategy and operations.

In view of the factors outlined above, global economic risks only have a very limited impact on STRATEC's business performance and business model. Moreover, long-term supply agreements with our customers minimize the potential implications of the crisis for STRATEC.

REPORT ON FORECASTS AND OTHER STATEMENTS CONCERNING THE COMPANY'S EXPECTED DEVELOPMENT

As previously announced, in May 2012 we published our company forecast extended by one year for the 2012 to 2014 financial years. This takes due account of the latest developments in the in-vitro diagnostics industry, additional customer information, and updated internal assessments.

STRATEC expects to generate sales of between € 125 million and € 139 million in 2012. Furthermore, annual average sales growth (CAGR) for the years 2012 to 2014 is expected to amount to between 14% and 16% based on 2011 sales figures (€ 116.6 million). The exceeding of the € 160 million sales mark expected for 2013 is based on current production figures and is linked to the market launches planned to have been implemented by then. We expect to generate an EBIT margin of between 17% and 19% in both 2012 and 2013.

Medium-term forecasting is influenced by ongoing consolidation in the diagnostics industry, planned market launches, approval dates, which can only be planned to a limited extent, and analyzer system generation changes. Due to scaling effects and given that the relative margin contribution from the maintenance and spare parts business is spread over several financial years, the earnings corridor has currently been defined very broadly (interaction between sales growth, % margin contribution of maintenance and spare parts business, and the resultant gross margin). STRATEC is currently still increasing its development expenditure to account for further projects newly acquired or in the contract signing stage. Our customer forecasts and additional forthcoming market launches give us reason to expect that our sales performance will show further slightly positive developments in the second half of the year.

Due to the immense debt accumulated by some countries and economic regions and the resultant potential implications (debt crisis), the level of budgeting liability remains low for all industries, and for the global economy as a whole. This situation continues to harbor risks for STRATEC's customers and suppliers, as a result of which STRATEC also faces economic risks. The ongoing difficult economic climate also means that STRATEC continues to face increased market risk.

Apart from this, since the assessment of the company's situation provided on March 12, 2012 upon the compilation of the Annual Report for the 2011 financial year, no new information has arisen which could lead to any change in our assessment of the company's expected development.

OPPORTUNITY AND RISK REPORT

We analyze and evaluate the risks facing the company and its business environment within the framework of our risk management system, which has been established as an early warning risk identification system. Furthermore, this system also includes a compliance system to ensure compliance with the relevant legal and industry-specific requirements.

STRATEC's business activities basically focus on sustainability and responsible behavior. In future, the company will document this in a sustainability report.

Apart from the factors outlined in the "Report on forecasts and other statements concerning the company's expected development", we do not see any changes compared with the risks and opportunities identified in the Group Management Report for the 2011 financial year dated March 12, 2012. Reference is made to the "Risk Report" section within the 2011 Group Management Report for details concerning our risk management system and our company's specific opportunity and risk profile.

CONSOLIDATED BALANCE SHEET

as of June 30, 2012
of STRATEC Biomedical AG

ASSETS in € thousands	06.30.2012	12.31.2011
NON-CURRENT ASSETS		
Goodwill	4,526	4,584
Other intangible assets	5,919	5,874
Property, plant and equipment	17,314	17,212
Interests in associates	392	351
Deferred tax assets	1,075	630
	29,226	28,651
CURRENT ASSETS		
Raw materials and supplies	10,667	8,269
Unfinished products, unfinished services	31,700	30,409
Finished products and goods	1,122	774
Trade receivables	17,125	15,331
Future receivables from construction contracts	5,479	5,992
Receivables from associates	84	122
Other receivables and other assets	2,636	1,679
Securities	244	222
Cash and cash equivalents	17,659	19,548
	86,716	82,346
TOTAL ASSETS	115,942	110,997

SHAREHOLDERS' EQUITY AND DEBT in € thousands	06.30.2012	12.31.2011
SHAREHOLDERS' EQUITY		
Share capital	11,703	11,675
Capital reserve	15,651	15,306
Revenue reserves	48,965	40,098
Consolidated net income	7,352	15,282
Other equity	950	870
	84,621	83,231
DEBT		
Non-current debt		
Non-current financial liabilities	8,671	9,167
Deferred taxes	1,167	1,352
	9,838	10,519
Current debt		
Current financial liabilities	816	777
Trade payables	6,727	3,955
Liabilities to associates	78	40
Other current liabilities	10,846	10,314
Current provisions	1,966	1,427
Income tax liabilities	1,050	710
	21,483	17,223
Deferred income and accrued expenses	0	24
TOTAL SHAREHOLDERS' EQUITY AND DEBT	115,942	110,997

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME*

for the Period from April 1 to June 30, 2012
of STRATEC Biomedical AG

in € thousands	04.01.-06.30.2012	04.01.-06.30.2011
Sales	29,402	26,406
Increase in volume of finished and unfinished products and unfinished services	1,408	2,676
Other own work capitalized	489	387
Overall performance	31,299	29,469
Other operating income	409	335
Cost of raw materials and supplies	14,251	13,762
Cost of purchased services	703	446
Personnel expenses	8,313	7,137
Other operating expenses	2,322	2,429
EBITDA	6,119	6,030
Amortization of intangible assets and depreciation of property, plant and equipment	1,044	898
EBIT	5,075	5,132
Net financial expenses	-182	-51
Operating result (EBT)	4,893	5,081
Current tax expenses	1,270	1,359
Deferred tax income	291	289
Consolidated net income	3,914	4,011
Income and expenses recognized directly in equity (after taxes)		
Hedging transactions	-81	0
Currency translation of foreign financial statements	111	100
Comprehensive income	3,944	4,111
Earnings per share in €	0.34	0.34
Number of shares used as basis	11,673,473	11,609,164
Earnings per share, diluted, in €	0.33	0.34
Number of shares used as basis, diluted	11,730,018	11,691,661

*Figures presented derived using total cost method.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME*

for the Period from January 1 to June 30, 2012
of STRATEC Biomedical AG

in € thousands	01.01.-06.30.2012	01.01.-06.30.2011
Sales	58,242	48,515
Increase in volume of finished and unfinished products and unfinished services	1,658	5,545
Other own work capitalized	970	740
Overall performance	60,870	54,800
Other operating income	625	446
Cost of raw materials and supplies	27,696	24,904
Cost of purchased services	1,096	839
Personnel expenses	16,610	14,073
Other operating expenses	4,650	4,680
EBITDA	11,443	10,750
Amortization of intangible assets and depreciation of property, plant and equipment	2,020	1,672
EBIT	9,423	9,078
Net financial expenses	-126	-165
Operating result (EBT)	9,297	8,913
Current tax expenses	2,608	2,264
Deferred tax income	663	315
Consolidated net income	7,352	6,964
Income and expenses recognized directly in equity (after taxes)		
Hedge transactions **	-81	0
Currency translation of foreign financial statements	161	-559
Comprehensive income	7,432	6,405
Earnings per share in €	0.63	0.60
Number of shares used as basis	11,674,895	11,577,248
Earnings per share, diluted, in €	0.63	0.60
Number of shares used as basis, diluted	11,723,741	11,691,307

*Figures presented derived using total cost method. The supplementary presentation based on the cost of sales method and provided solely for information reasons can be found on Page 13.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME*

for the Period from January 1 to June 30, 2012
of STRATEC Biomedical AG

in € thousands	01.01.-30.06.2012	01.01.-30.06.2011
Sales	58,242	48,515
Cost of sales	39,880	31,416
Gross profit	18,362	17,099
Research and development expenses	3,186	2,619
Information only: Capitalized research and development expenses	7,873	7,119
Information only: Total research and development expenses	11,059	9,738
Distribution costs	2,564	2,352
General administrative expenses	3,107	2,786
Other operating income	566	606
Other operating expenses	648	870
EBIT	9,423	9,078
Net financial expenses	-126	-165
Operating result (EBT)	9,297	8,913
Current tax expenses	2,608	2,264
Deferred tax income	663	315
Consolidated net income	7,352	6,964
Income and expenses recognized directly in equity (after taxes)		
Hedging transactions	-81	0
Currency translation of foreign financial statements	161	-559
Comprehensive income	7,432	6,405
Earnings per share in €	0.63	0.60
Number of shares used as basis	11,674,895	11,577,248
Earnings per share, diluted, in €	0.63	0.60
Number of shares used as basis, diluted	11,723,741	11,691,307

*Figures presented derived using the cost of sales method. This disclosure is to be viewed as a supplement to, rather than as a substitute for the statement of comprehensive income using the total cost method. This disclosure does not form part of the respective accounting requirements.

CONSOLIDATED CASH FLOW STATEMENT

for the Period from January 1 to June 30, 2012
of STRATEC Biomedical AG

in € thousands	01.01.-06.30.2012	01.01.-06.30.2011
Consolidated net income (after taxes)	7,352	6,964
Depreciation and amortization	2,020	1,672
Current income tax expenses	2,608	2,264
Income taxes paid less income taxes received	-2,351	-2,060
Financial income	-128	-88
Financial expenses	98	252
Interest paid	-98	-157
Interest received	97	58
Other non-cash expenses	304	287
Other non-cash income	-1,134	-740
Cash flow	8,768	8,452
Change in deferred taxes through profit or loss	-663	-315
Profit from disposal of non-current assets	-13	-116
Increase in inventories, trade receivables and other assets	-6,154	-9,717
Increase in trade payables and other liabilities	3,622	4,306
Inflow of funds from operating activities	5,560	2,610
Incoming payments from disposals of non-current assets		
Property, plant and equipment	26	134
Outgoing payments for investments in non-current assets		
Intangible assets	-165	-113
Property, plant and equipment	-807	-1,311
Prepayments made / assets under construction	-173	-198
Financial assets	-30	0
Outflow of funds for investment activities	-1,149	-1,488
Incoming payments from taking up of financial liabilities	76	2,515
Outgoing payments for repayment of financial liabilities	-565	-287
Incoming payments for issues of shares for employee stock option programs	319	841
Dividend payment	-6,415	-5,778
Outflow of funds for financing activities	-6,585	-2,709
Cash-effective change in cash and cash equivalents	-2,174	-1,587
Cash and cash equivalents at beginning of period	19,548	13,222
Change in cash and cash equivalents due to changes in exchange rates	285	-144
Cash and cash equivalents at end of period	17,659	11,491

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the Period from January 1 to June 30, 2012
of STRATEC Biomedical AG

JANUARY - JUNE 2011

in € thousands	Share capital	Capital reserve	Revenue reserves	
			Accumulated net income	Free revenue reserves
Balance at 01.01.2011	11,569	13,915	22,445	10,540
Dividend payment				
Issue of subscription shares from stock option programs, less costs of capital issue after taxes	70	771		
Allocations due to stock option plans		82		
Allocation to free revenue reserves				3,000
Profit carried forward			4,261	
Issue of treasury stock to employees		-148		
Comprehensive income				
Balance at 06.30.2011	11,639	14,620	26,706	13,540

JANUARY - JUNE 2012

in € thousands	Share capital	Capital reserve	Revenue reserves	
			Accumulated net income	Free revenue reserves
Balance at 01.01.2012	11,675	15,306	26,706	13,392
Dividend payment				
Issue of subscription shares from stock option programs, less costs of capital issue after taxes	28	282		
Allocations due to stock option plans		63		
Value adjustments recognized directly in equity				
Allocation to free revenue reserves				3,000
Profit carried forward			5,867	
Issue of treasury stock to employees				
Comprehensive income				
Balance at 06.30.2012	11,703	15,651	32,573	16,392

Consolidated net income	Other equity		Group equity
	Treasury stock	Currency translation	
13,039	-417	788	71,879
-5,778			-5,778
			841
			82
-3,000			0
-4,261			0
	205		57
6,964		-559	6,405
6,964	-212	229	73,486

Consolidated net income	Other equity			Group equity
	Hedging transactions	Treasury stock	Currency translation	
15,282	0	-212	1,082	83,231
-6,415				-6,415
				310
				63
	-81		161	80
-3,000				0
-5,867				0
				0
7,352				7,352
7,352	-81	-212	1,243	84,621

NOTES TO THE GROUP INTERIM REPORT

for the period from January 1 to June 30, 2012
of STRATEC Biomedical AG

Summary of principal accounting and valuation methods

The consolidated financial statements of STRATEC Biomedical AG as of December 31, 2011 were prepared in accordance with the International Financial Reporting Standards (IFRS) as adopted by the EU valid at the balance sheet date. In the interim report as of June 30, 2012, which has been prepared on the basis of International Accounting Standard (IAS) 34 "Interim Financial Reporting", application has been made of the same accounting methods as in the consolidated financial statements for the 2011 financial year.* Application has also been made of all interpretations of the International Financial Reporting Interpretations Committee (IFRIC) with binding effect as of June 30, 2012.

There were no indications of any potential impairment in goodwill at the balance sheet date.

The company's interim reports are neither audited, nor subject to an audit review, by the group auditor, Wirtschaftstreuhand GmbH Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Stuttgart.

Reference is made to the consolidated financial statements of STRATEC Biomedical AG as of December 31, 2011 with regard to further information concerning the individual accounting and valuation methods applied.

The Group's currency is the euro. Unless otherwise indicated, all amounts have been stated in thousand euros (€ thousand).

Segment disclosures

There have been no changes in the segmentation of the Group's results compared with the consolidated financial statements as of December 31, 2011.

Segment data by operating segment for the period from January 1 to June 30, 2012

in € thousands	Instrumentation	All other segments	Reconciliation	Total
Sales	60,878	1,779	-4,415	58,242
EBITDA	12,325	-1,005	123	11,443
EBIT	10,810	-1,092	-295	9,423
EBT	10,694	-1,109	-288	9,297
Net income	8,474	-817	-305	7,352
Assets	130,061	3,610	-17,729	115,942

*The presentation of the statement of comprehensive income using the cost of sales method is to be viewed as a supplement to, rather than as a substitute for the disclosures presented in accordance with IFRS. This disclosure does not form part of the respective accounting requirements.

Segment data by operating segment for the period from January 1 to June 30, 2011

in € thousands	Instrumentation	All other segments	Reconciliation	Total
Sales	48,750	1,985	-2,220	48,515
EBITDA	11,047	-297	0	10,750
EBIT	9,830	-345	-407	9,078
EBT	9,681	-361	-407	8,913
Net income	7,604	-457	-183	6,964
Assets	119,520	3,236	-15,919	106,837

The breakdown of sales by geographical region represents the distribution of the STRATEC Group's products. As the customers of the STRATEC Group generally supply their country outlets and customers from their own central distribution centers, however, this breakdown of sales does not represent the geographical distribution of the final operating locations of the STRATEC Group's analyzer systems.

Sales can be broken down by geographical regions (customer locations) as follows:

in € thousands	Germany	EU	Other	Total
January - June 2012	9,243	24,735	24,264	58,242
	15.9%	42.5%	41.6%	100.0%

in € thousands	Inland	EU	Sonstige	Gesamt
January - June 2011	9,262	29,467	9,786	48,515
	19.1%	60.7%	20.2%	100.0%

Research and development expenses

The expenses relating to research and project management, and to development services not fulfilling the capitalization criteria set out in IAS 38, amounted to € 3.2 million in the first six months of the 2012 financial year (previous year: € 2.6 million). These have been reported, mainly as personnel expenses, in the company's consolidated statement of comprehensive income. Moreover, procurement volumes of around € 0.4 million (previous year: € 0.5 million) were incurred during the period under report in connection with materials used in research and development. These have been included in the cost of materials item. The STRATEC Group invested a total amount of € 11.1 million in research and development in the first six months of the 2012 financial year (previous year: € 9.7 million). As a percentage of sales (excluding development and services), this corresponds to a ratio of 21.5% (previous year: 20.5%).

Shareholders' equity

The development in shareholders' equity at the STRATEC Group has been presented in the consolidated statement of changes in equity on Pages 15 and 16. The number of ordinary shares with a nominal value of € 1.00 each issued by STRATEC AG as of June 30, 2012, amounts to 11,703,045. These are all bearer shares.

Disclosures on the volume of treasury stock and on subscription rights held by members of the company's executive and supervisory bodies and its employees pursuant to § 160 (1) Nos. 2 and 5 of the German Stock Corporation Act (AktG)

STRATEC AG owned a total of 12,223 treasury stock at the interim balance sheet date. This corresponds to a prorated amount of € 12,223.00 of the company's share capital and to a 0.11 % share of its equity.

Stock option programs

Members of the Board of Management / Managing Directors and employees held the following numbers of subscription rights (share option rights) at the interim balance sheet date:

	Board of Management / Managing Directors	Employees	Total
Outstanding on 01.01.2012	102,000	52,150	154,150
Issued	45,000	7,050	52,050
Exercised	22,500	5,650	28,150
Lapsed	0	100	100
Outstanding on 06.30.2012	124,500	53,450	177,950

A total of 7,050 stock option rights were granted to company employees and a total of 45,000 stock option rights to members of the Board of Management on the basis of option agreements dated February 1, 2012, February 23, 2012, May 24, 2012 and June 1, 2012.

A total of 22,500 stock option rights were exercised by members of the Board of Management and a total of 5,650 stock option rights by employees in the first six months of the 2012 financial year. To service these stock option rights, 28,150 shares were created from conditional capital.

Furthermore, 100 stock option rights lapsed in the period under report.

Employees

Including temporary employees the STRATEC Group had a total workforce of 524 employees as of June 30, 2012 (previous year: 466).

Major events after the interim reporting date

No events of particular significance with material implications for the business performance of our Group have occurred since the interim balance sheet date.

Responsibility statement

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group, and the interim management report of the Group includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group in the remainder of the financial year.

ADDITIONAL INFORMATION

FINANCIAL CALENDAR

July 24, 2012	Interim Report as of June 30, 2012
October 24, 2012	Interim Report as of September 30, 2012
November 12, 2012	STRATEC Analyst & Investor Day, Frankfurt am Main, Germany

Furthermore, based on current planning, STRATEC will be taking part in the following capital market conferences in 2012:

August 2012	Commerzbank Sector Conference, Frankfurt am Main, Germany
September 2012	Goldman Sachs European Medtech and Healthcare Services Conference, London, UK Morgan Stanley Global Healthcare Conference, New York City, USA DZ Bank 10 th German Healthcare Conference, Zürich, Switzerland UBS Global Life Sciences Conference, New York City, USA Berenberg Bank and Goldman International Inaugural German Corporate Conference, Munich, Germany
November 2012	German Equity Forum, Frankfurt am Main, Germany HSBC 5 th HealthCare Conference, Frankfurt am Main, Germany

Partially incomplete / subject to amendment

ABOUT STRATEC

STRATEC Biomedical AG designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE 0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information about STRATEC is available on the internet at www.stratec.com.

IMPRINT

Published by

STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany

Phone: +49 7082 7916-0
Fax: +49 7082 7916-999
info@stratec.com
www.stratec.com

Investor Relations

ANDREAS KÜNZEL
Phone: +49 7082 7916-185
Fax: +49 7082 7916-999
a.kuenzel@stratec.com

ANDRE LOY
Phone: +49 7082 7916-190
Fax: +49 7082 7916-999
a.loy@stratec.com

NOTICE

Forward-looking statements involve risks: This interim report contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

This interim report contains various disclosures of an economic nature that do not form part of the relevant accounting requirements. These disclosures are to be viewed as a supplement to, rather than as a substitute for the disclosures made in accordance with IFRS.

Discrepancies may arise throughout this interim report on account of mathematical rounding up or down in the course of addition.

This interim report is also available in German.

STRATEC BIOMEDICAL AG

Gewerbestr. 37
75217 Birkenfeld
Germany

Phone: +49 7082 7916-0

Fax: +49 7082 7916-999

info@stratec.com

www.stratec.com